logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

An Uncharacteristically Slow August Gives Way to an Uncertain Fall

September 17, 2020
-
Market Access News
-
Posted by MORSE - 2 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): August 2020 Trends and Insights

 

August 2020 Highlights:

  • 2 products completed CADTH review
  • 2 products initiated pCPA negotiations
  • 1 negotiation was completed with an LOI
  • 0 negotiations were closed without an LOI
  • 0 files were closed without negotiation

 

Files Under pCPA Consideration:

CADTH issued 2 new recommendations in August (25 files as of August 31).

PRODUCT INDICATION SPONSOR HTA REC’N* DATE
Soliris
(eculizumab)
Neuromyelitis Optica spectrum disorder Alexion CDR August 19
Cablivi
(caplacizumab)
Acquired thrombotic thrombocytopenic purpura (aTTP) Sanofi-Genzyme CDR August 26

* REC’N DATE = Date of CDEC Final Recommendation (CDR), Date Notification to Implement Issued (pCODR)

 

Signals Decoded:

 

The number of files under pCPA consideration stood at 25 at the end of August; the highest level since there were 26 files in this process phase at the end of August 2018.
 
Soliris enters the pCPA process for the third time, having previously been negotiated for two indications (aHUS and PNH).  While an agreement was negotiated for the PNH indication, the August 2020 recommendation for Neuromyelitis Optica spectrum disorder marks the first time Soliris has received a “positive” recommendation from CADTH.

Negotiation Initiation:

The pCPA initiated 2 new negotiations in August (28 active negotiations as of August 31, 2020)

PRODUCT INDICATION SPONSOR CATEGORY INITIATE DATE TTI*
Rituxan SC
(rituximab)
Chronic lymphocytic leukemia Roche Other August 11 N/A
Xospata
(gilteritinib)
Acute Myeloid Leukemia Astellas pCODR August 17 74

* TTI = Time to Initiate in calendar days

 

Signals Decoded:

 

Rituxan SC re-enters active negotiations just two years after reaching an agreement for the same indication (CLL – August 2018), presumably due to the recent entry of multiple biosimilar versions of IV rituximab.

 

The overall volume of files under pCPA management (under consideration + active negotiation) continues to climb and is at the highest level (53) since September 2019.

Completed/Closed Negotiations:

The pCPA completed 1 negotiation with a Letter of Intent (LOI) in August 2020.

PRODUCT INDICATION SPONSOR LOI DATE TTN*
Mylotarg
(gemtuzumab ozogamicin)
Acute Myeloid Leukemia Pfizer August 12 56

* TTN = Time to Negotiate in calendar days

 

 

Signals Decoded:

 

The number of files under pCPA management for “extended periods” continues to climb.  Kanuma is the longest active negotiation (started November 2018), while Pomalyst has been under consideration since October 2019.

Signals Decoded:

 

After a moderately active July, the pCPA adjudicated a single file in August 2020.  Historically, the last full month of summer has been more active, with pCPA completing 7 agreements in each of August 2018 and 2019.

 
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share
Tags
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
Numbers Steady after Limited September Outputs from pCPA and CADTH
NEXT POST →
MORSE Consulting Bolsters Private Payer Expertise

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
An Uncharacteristically Slow August Gives Way to an Uncertain Fall